Status:
RECRUITING
Effects of Coenzyme Q10 Supplement on Cardiovascular Risk Factors in Subjects at High Risk of Metabolic Syndrome
Lead Sponsor:
Tian Zezhong
Conditions:
Metabolic Syndrome
Cardiovascular Diseases
Eligibility:
All Genders
30-90 years
Phase:
NA
Brief Summary
This study aims to evaluate the ameliorating effect of coenzyme Q10 supplementation on cardiovascular risk factors in high risk population for metabolic syndrome, including blood lipid metabolism, ins...
Eligibility Criteria
Inclusion
- Metabolic syndrome or high-risk groups with metabolic syndrome are defined as subjects with metabolic syndrome according to the International Diabetes Federation (IDF) Chinese Adult Criteria, and high-risk groups are defined as those who meet at least two MetS risk factors. The specific criteria are as follows:
- Aged 30-90 years old;
- Two or more of following are acceptable:
- <!-- -->
- Abdominal obesity (central obesity): waist circumference \>=90 cm for men and \>=80cm for women;
- Hyperglycemia: fasting blood glucose ≥ 5.6mmol/L or taking hypoglycemic drugs;
- Hypertension: systolic blood pressure \>=130mmHg and (or) diastolic blood pressure \>=85mmHg or taking blood pressure medications;
- Fasting TG\>=1.70mmol/L or taking antihyperlipidemic drug;
- Fasting HDL-C\<1.04 mmol/L for men, \<1.29 mmol/L for women or taking antihyperlipidemic drug; 3) Sign informed consent and insist on participating in the research.
Exclusion
- 1\) Take drugs/dietary supplements, such as aspirin, fish oil and etc., that affect platelet function in recently six months; 2) blood system disease or infection; 3) Blood pressure \>=160/100mmHg; 4) Low platelet count (whole blood platelet\<100 x 10\^9/mL); 5) Abnormal hemoglobin (male \<120g/L, female \<110g/L); 6) Low hematocrit (male \<40%, female \<37%); 7) Prothrombin time (PT) is outside the normal reference range; 8) Pregnant women or nursing mothers; 9) Abnormal menstrual cycle, taking birth control pills or hormone replacement therapy; 10) Gastric ulcer, liver or kidney dysfunction.
Key Trial Info
Start Date :
September 11 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06506630
Start Date
September 11 2023
End Date
December 30 2024
Last Update
July 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
School of Public Health (Shenzhen), Sun Yat-sen University
Shenzhen, China, 518107